Support Tool for Antibiotic Allergy deLabeling
Recruiting now · Not applicable
Conditions studied: Antibiotic Allergy
In brief
Antibiotic allergy labels (AAL) are reported in 7% of inpatient's charts, especially for beta-lactams (86% of AAL, i.e., prevalence of 6%). They are associated with increased length of hospital stay, and use of second-line and broad-spectrum antibiotics. Allergy workups are able to invalidate the majority of these AAL but are time-consuming and require invasive skin and provocation testing. The investigators recently evaluated, for the first time in Europa, a strictly non-invasive delabeling protocol using a questionnaire, medical file search and contact with primary care health care workers in 200 adult internal medicine inpatients with a beta-lactam AAL. Up to half of the AAL could be removed or refined, demonstrating the potential of this strategy. In this project, they aim to assess the impact of using the non-invasive 'AAL-fact-check' tool in a multicenter study, on antibiotic selection, and clinical, antimicrobial, and economic endpoints, as compared with the standard of care (i.e., no AAL-fact-check tool).
Key facts
- Study ID
- NCT06771440
- Run by
- Universitaire Ziekenhuizen KU Leuven
- People needed
- 3000
- Starts
- 2025-03-10
- Expected to finish
- 2026-05-01
- Last updated by the study team
- 2025-12-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Hospitalized patients
- AAL for one or more beta-lactams
You may not qualify if…
- Age younger than 18
- Previous enrolment in this study
Where it is running
- University Hospitals Leuven — Leuven, Belgium (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.